Nuclea Biotechnologies Lands $3,400,000 New Funding

  • Feed Type
  • Date
    10/22/2009
  • Company Name
    Nuclea Biotechnologies
  • Mailing Address
    105 South Street Pittsfield, MA 01201
  • Company Description
    Nuclea Biotechnologies’ primary mission is to conduct genomic research in the oncology field so as to discover biomarkers and gene or protein expression profiles that are unique to oncologic diseases. Nuclea Biotechnologies seeks to harness this knowledge to develop clinically validated molecular diagnostic and pharmacogenomic products and services that can be used, among other things, to provide clinically useful information on the likelihood of recurrence and metastasis of cancer, as well as to predict the likelihood that a patient will respond to a cancer therapy. Nuclea utilizes a translational medicine-based approach, which allows the conversion of laboratory results into new ways of diagnosing and treating patients. This approach entails using tumor biopsies and associated clinical data to link specific genes and proteins to the characteristics of specific cancers. Information obtained from preliminary human studies can be used to refine understanding of the biological principles
  • Website
    http://www.nucleabiomarkers.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $3,400,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.